The path to eradication of rubella.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
07 Dec 2023
Historique:
received: 19 09 2023
revised: 27 10 2023
accepted: 04 11 2023
medline: 4 12 2023
pubmed: 17 11 2023
entrez: 16 11 2023
Statut: ppublish

Résumé

Since 1969, rubella and its harmful effect on fetuses infected in utero can be prevented by rubella vaccine, usually given in combination with measles vaccine. The rubella vaccine is highly protective both in children and in adults including women intending to become pregnant. Owing to the use of combined measles and rubella vaccines, congenital rubella infection has been eliminated from the Western Hemisphere and nearly all of Europe. Such combined vaccination is now being applied throughout the world, posing the possibility of eventual rubella eradication. The existence of viruses of animals related to rubella does not appear to be a barrier to eradication of the human virus. However, persistent rubella virus in infants infected in utero and of immunosuppressed patients with granulomas may pose a problem for eradication. Nevertheless, this review posits that eradication of rubella is now feasible if routine vaccination of infants and surveillance for chronic infection are correctly applied.

Identifiants

pubmed: 37973510
pii: S0264-410X(23)01326-9
doi: 10.1016/j.vaccine.2023.11.014
pii:
doi:

Substances chimiques

Rubella Vaccine 0
Measles Vaccine 0
Measles-Mumps-Rubella Vaccine 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

7525-7531

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Susan E Reef (SE)

Atlanta, GA 30345, USA. Electronic address: susanreef4@gmail.com.

Joseph P Icenogle (JP)

575 Pharr RD NE, P.O. Box 550081, Atlanta, GA 30355, USA. Electronic address: Jnmadice2@gmail.com.

Stanley A Plotkin (SA)

University of Pennsylvania, Vaxconsult, 4650 Wismer Rd., Doylestown, PA 18902, USA. Electronic address: Stanley.plotkin@vaxconsult.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH